Citigate Dewe Rogerson supports Acacia Pharma’s proposed £150m IPO
Acacia Pharma, a speciality pharma company developing “supportive care” medicines, is working with Citigate Dewe Rogerson’s Life Sciences team as a retained adviser while it plans a listing on the main market of the London Stock Exchange.
Cambridge-based Acacia Pharma develops new supportive care medicines to prevent and treat the side effects of surgery, cancer or cancer treatment.
Financial and corporate comms specialist Citigate Dewe Rogerson shall provide support in the areas of financial PR, media strategy, messaging and outreach, in addition to website content.
The company is aiming to raise £150 million in its IPO, which was announced in a statement to the stock exchange earlier this week. New funds will advance Acacia’s plans for two lead products it is developing to prevent, and treat, nausea and vomiting in people after surgery and chemotherapy. The IPO is expected in October.
Mark Swallow, David Dible and Pip Batty make up the Citigate Dewe Rogerson team advising Acacia Pharma.